MedTrace Logo

Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma

NCT06516224 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-07-23

No results posted yet for this study

Summary

This 6 month, comparative study assesses the benefit of a dermocosmetic regimen (Serum B3 + B3 retinol night cream) for 6 months compared to hydroquinone 4% (the gold standard in hyperpigmentation) followed by the dermocosmetic regimen for 3 months or the Kligman Trio for 3 months followed by the dermocosmetic regimen for 3 months in adult women with melasma on the face.

Conditions

  • Melasma

Interventions

OTHER

Liftactiv® B3 Serum

In Group 1: Application once daily for 6 months, 3-4 drops twice a day (morning before the sunscreen and evening) In Group 2 and Group 3: Application once daily, 3-4 drops twice a day (morning before the sunscreen and evening) for 3 months following HQ4% or Kligman Trio treatment.

OTHER

Liftactiv® B3 retinol night cream

In Group 1: Application once daily (morning) for 6 months In Group 2 and Group 3: During week 1, apply 2 evenings/week. During week 2, apply every other evening. During week 3, apply every evening. During nights when retinol night cream is not applied, replace with Mineral 89 cream for 3 months following HQ4% or Kligman Trio treatment.

OTHER

Sunscreen UVAage® Inter SPF 50+

twice daily (morning and beginning of the afternoon)

OTHER

Mineral 89 cream

2 drops in the morning before sunscreen application for 6 months

Sponsors & Collaborators

  • Cosmetique Active International

    lead INDUSTRY

Principal Investigators

  • Claire Deloche-Bensmain, PhD · La Roche Posayl Laboratoires Dermatologiques

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-15
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06516224 on ClinicalTrials.gov